OCT 08, 2019 5:32 PM PDT

New Type of CAR T-Cell Therapy Headed for Clinical Trials

WRITTEN BY: Carmen Leitch

Scientists have been trying to use the immune system in cancer patients’ bodies to fight cancer. The T-cells of the immune system can kill cells that are infected with a virus or that are cancerous. In CAR T-cell therapy, a patient’s T-cells are removed from the bloodstream and genetically modified in the laboratory so that they can identify cancer cells and kill them more efficiently after being reintroduced into the patient’s body. One new type of CAR T-cell therapy involves a protein associated with cancer cells, the B cell-activating factor receptor (BAFF-R). In the first test of this therapy, human leukemia and lymphoma cells that were resistant to other therapeutics were successfully eradicated. The work, which has been reported in Science Translational Medicine, will be used in a clinical trial next year on patients that experienced relapse after immunotherapy treatments.

The Food and Drug Administration has approved therapies that target a protein called CD19 on cancerous B cells, but around twenty to thirty percent of patients with leukemia and lymphoma that receive these treatments relapse. The effectiveness wears off after a few years, and their cancer comes back.

"One major obstacle to current CAR T therapy is that in up to a third of these patients, the tumor is actually smart and comes back because it has learned how to no longer express the target that's recognized by the original immunotherapy," explained the principal study author Larry Kwak, M.D., Ph.D., vice president and deputy director of City of Hope's comprehensive cancer center. "To combat that, City of Hope research has found a new, and potentially more effective, target for CAR T cell therapy against B cell leukemias and lymphomas. We plan to open a clinical trial next year using the BAFF-R CAR T cell therapy."

"This new treatment could change the face of leukemia and lymphoma treatment in the U.S. and worldwide," added Kwak,  who co-led the study with Hong Qin, Ph.D., a research professor in City of Hope's Department of Hematology & Hematopoietic Cell Transplantation.

In this work, an animal model of CD19 human tumors that resist therapy were exposed to BAFF-R CAR T-cell therapy. The researchers saw longer survival times and a reduction in tumors. There was complete tumor regression in an animal model of Burkitt lymphoma after only one treatment. In animals carrying human tumors with and without CD19 that were then given the BAFF-R CAR T-cell therapy or CD19 CAR T-cell therapy, both types of tumor cells were eradicated by the BAFF-R but not the CD19 CAR T therapy.

The researchers also compared the therapies using tumor samples from patients that had gotten CAR T treatment targeting CD19. The response to the CD19-directed therapy was diminished, while BAFF-R CAR T-cell therapy was consistently active.

"We did a head-to-head comparison of two new therapies, and our data showed that our BAFF-R CAR T therapy actually did a better job than FDA-approved CD19 CAR T therapies," Qin said. "If these results continue, we will pursue BAFF-R CAR T therapy as a kind of frontline CAR T therapy treatment for lymphoma and leukemia patients."

Sources: AAAS/Eurekalert! via City of Hope, Science Translational Medicine

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JUN 19, 2020
Cell & Molecular Biology
Learning More About How Cells Control a Death Pathway
JUN 19, 2020
Learning More About How Cells Control a Death Pathway
Scientists have published complementary studies in Nature Communications that have greatly advanced our understanding of ...
JUN 29, 2020
Drug Discovery & Development
Staring into Deep Red Light Improves Eyesight
JUN 29, 2020
Staring into Deep Red Light Improves Eyesight
Researchers from UCL have found that staring into a deep red light for just three minutes per day can significantly impr ...
JUL 06, 2020
Microbiology
SARS-CoV-2 Makes Cells Sprout Infectious Tentacles
JUL 06, 2020
SARS-CoV-2 Makes Cells Sprout Infectious Tentacles
The pandemic coronavirus has caused a wide range of different symptoms, and as time goes on, we may find that it can hav ...
JUL 10, 2020
Cell & Molecular Biology
Gut Pathogen Linked to Reactive Arthritis
JUL 10, 2020
Gut Pathogen Linked to Reactive Arthritis
When bacteria escape from the gastrointestinal tract, they can cause serious health problems.
JUL 12, 2020
Cell & Molecular Biology
Lung Cancer is Different in Non-Smokers
JUL 12, 2020
Lung Cancer is Different in Non-Smokers
Not everyone that gets lung cancer is a current or former smoker, and researchers have now found that lung cancer is dif ...
JUL 28, 2020
Immunology
Neonatal Origins of Chronic Inflammatory Disease
JUL 28, 2020
Neonatal Origins of Chronic Inflammatory Disease
From birth, our genes write the story of our lives. For many people who develop chronic immune and inflammatory diseases ...
Loading Comments...